Journal of Chemistry
5
Conflict of Interests
bearing arylsulfonyl moiety: novel celecoxib analogs as potent
anti-inflammatory agents,” European Journal of Medicinal
Chemistry, vol. 80, pp. 416–422, 2014.
e authors declare that there is no conflict of interests
regarding the publication of this paper.
[13] H. A. Abdel-Aziz, K. A. Al-Rashood, H. A. Ghabbour, H.-
K. Fun, and T. S. Chia, “1-(4-Methylphenyl)-2-(phenylsul-
fonyl)ethanone,” Acta Crystallographica Section E, vol. 68, part
4, Article ID o1033, p. o1033, 2012.
Acknowledgment
[14] G. M. Sheldrick, “A short history of SHELX,” Acta Crystallo-
e authors would like to extend their sincere appreciation
to the Deanship of Scientific Research at the King Saud Uni-
versity for its funding of this research through the Research
Group Project no. RGP-VPP-321.
graphica Section A, vol. 64, no. 1, pp. 112–122, 2008.
[15] S. Bala, G. Uppal, A. Kajal, S. Kamboj, and V. Sharma,
“Hydrazones as promising lead with diversity in bioactivity-
therapeutic potential in present scenario,” International Journal
of Pharmaceutical Sciences Review and Research, vol. 18, no. 1,
pp. 65–74, 2013.
References
[16] H. A. Abdel-Aziz, H. A. Ghabbour, M. A. Bhat, and H.-K. Fun,
“Microwave-assisted synthesis and characterization of certain
oximes, hydrazones and olefins derived from ꢀ-keto sulfones,”
Journal of Chemistry, vol. 2014, Article ID 532467, 6 pages, 2014.
[1] P. Vicini, M. Incerti, P. la Colla, and R. Loddo, “Anti-HIV eval-
uation of benzo[d]isothiazole hydrazones,” European Journal of
Medicinal Chemistry, vol. 44, no. 4, pp. 1801–1807, 2009.
[2] J. Jain, Y. Kumar, R. Sinha, R. Kumar, and J. Stables, “Menthone
aryl acid hydrazones: a new class of anticonvulsants,” Medicinal
Chemistry, vol. 7, no. 1, pp. 56–61, 2011.
[3] P. Dandawate, K. Vemuri, E. M. Khan, M. Sritharan, and S. Pad-
hye, “Synthesis, characterization and anti-tubercular activity
of ferrocenyl hydrazones and their ꢀ-cyclodextrin conjugates,”
Carbohydrate Polymers, vol. 108, no. 1, pp. 135–144, 2014.
[4] C. M. C. Ernest, “Antibacterial nitrofurfurylidene derivatives
and methods of using same,” US Patent, 3290213 A, 1966.
[5] H. A. Abdel-Aziz, H. A. Ghabbour, W. M. Eldehna, M.
M. Qabeel, and H.-K. Fun, “Synthesis, crystal structure and
biological activity of cis/trans amide rotomers of (Z)-Nꢀ-(2-
oxoindolin-3-ylidene)formohydrazide,” Journal of Chemistry,
vol. 2014, Article ID 760434, 7 pages, 2014.
[6] K. Effenberger, S. Breyer, and R. Schobert, “Modulation of
doxorubicin activity in cancer cells by conjugation with fatty
acyl and terpenyl hydrazones,” European Journal of Medicinal
Chemistry, vol. 45, no. 5, pp. 1947–1954, 2010.
[7] T. Aboul-Fadl, A. Kadi, and H. A. Abdel-Aziz, “Novel N,
Nꢀ-Hydrazino-bis-isatin Derivatives with Selective Activity
Against Multidrug-Resistant Cancer Cells,” US Patent no.
20120252860, 2012.
[8] H. A. Abdel-Aziz, T. Elsaman, A. Al-Dhfyan, M. I. Attia,
K. A. Al-Rashood, and A. R. M. Al-Obaid, “Synthesis and
anticancer potential of certain novel 2-oxo-N’-(2-oxoindolin-3-
ylidene)-2H-chromene-3-carbohydrazides,” European Journal
of Medicinal Chemistry, vol. 70, pp. 358–363, 2013.
[9] A. M. Alafeefy, H. A. Abdel-Aziz, D. Vullo et al., “Inhibition of
carbonic anhydrases from the extremophilic bacteria
Sulfurihydrogenibium yellostonense (SspCA) and S. azorense
(SazCA) with a new series of sulfonamides incorporating
aroylhydrazone-, [1,2,4]triazolo[3,4-ꢁ][1,3,4]thiadiazinyl- or 2-
(cyanophenylmethylene)-1,3,4-thiadiazol-3(2ꢂ)-yl moieties,”
Bioorganic & Medicinal Chemistry, vol. 22, no. 1, pp. 141–147,
2014.
[10] G. Wozel and C. Blasum, “Dapsone in dermatology and
beyond,” Archives of Dermatological Research, vol. 306, no. 2, pp.
103–124, 2014.
[11] Y. M. Markitanov, V. M. Timoshenko, and Y. G. Shermolovich,
“ꢀ-Keto sulfones: preparation and application in organic syn-
thesis,” Journal of Sulfur Chemistry, vol. 35, no. 2, pp. 188–236,
2014.
[12] H. A. Abdel-Aziz, K. A. Al-Rashood, K. E. H. Eltahir, and G.
M. Suddek, “Synthesis of N-benzenesulfonamide-1H-pyrazoles